<DOC>
	<DOCNO>NCT02636270</DOCNO>
	<brief_summary>With study want investigate pharmacokinetic ( PK ) effect single injection rhIGF-1 patient PAPP-A2 mutation compare heterozygous carrier healthy control . This follow treatment PAPP-A2 deficient patient IGF-1 period one year ass growth velocity . Additionally want describe phenotypic characteristic patient PAPP-A2 deficiency .</brief_summary>
	<brief_title>IGF-1 Treatment Individuals With Short Stature Due PAPP-A2 Deficiency</brief_title>
	<detailed_description>The 24-hour pharmacokinetic response free total IGF-1 IGF bind protein-3 ( IGFBP-3 ) single dose rhIGF-1 ( 120 mcg/kg ) three patient PAPP-A2 mutation compare four unaffected heterozygous relative 2 healthy adult control . One-year trial rhIGF-1 standard dose give two young male PAPP-A2 mutation . The primary end point trial first year height velocity . Secondary outcome include change height SDS , change height velocity SDS , change whole body lumbar spine bone mineral density . Description additional phenotypic characteristic patient PAPP-A2 mutation study glucose insulin metabolism , body composition , bone geometry bone density treatment rhIGF-1 .</detailed_description>
	<mesh_term>Dwarfism</mesh_term>
	<criteria>PAPPA2 deficient Defect PAPPA2 ( heterozygous homozygous mutation ) Healthy Volunteers Between age 18 30 In general good health Any medication ( exception contraceptive ) Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>